Private and confidential
December 2019
1
December 2019 Private and confidential 1 Presentation Disclaimer - - PowerPoint PPT Presentation
December 2019 Private and confidential 1 Presentation Disclaimer The information contained in this document (the Presentation) has been prepared by SV Pharma Limited (SVP). SVP is a private limited company. This Presentation has not
Private and confidential
December 2019
1
The information contained in this document (the “Presentation”) has been prepared by SV Pharma Limited (“SVP”). SVP is a private limited company. This Presentation has not been verified and is subject to material updating, revision and verification and amendment without notice. This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (as amended) (“FSMA”) and therefore it is being provided for information purposes only. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. While the information contained herein has been prepared in good faith, neither SVP nor any of its current or proposed directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof,
expressly disclaimed. Accordingly, neither SVP nor any of its current or proposed directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct
errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation. The views of the SVP’s management/directors and/or its partners/representatives set out in this Presentation could ultimately prove to be incorrect. No warranty, express or implied, is given by the presentation of these figures here and investors should place no reliance on SVP’s estimates cited in this Presentation. This Presentation may contain “forward-looking statements” that involve substantial risks and uncertainties, and actual outcome and developments may differ materially from those expressed or implied by these statements or a variety of factors. These forward-looking statements are statements regarding SVP’s intentions, beliefs or current expectations concerning, among other things, SVP’s performance, financial condition, prospects, growth, strategies and the industry in which SVP operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and SVP does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation. This Presentation should not be considered as the giving of investment advice by the SVP or any of its directors, officers, agents, employees or advisers. In particular, this Presentation does not constitute or form part of any offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in these slides or the Presentation or on the completeness, accuracy or fairness thereof. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters. Neither this Presentation nor any copy of it may be (a) taken or transmitted into Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a “Restricted Territory”), their territories or possessions; (b) distributed to any U.S. person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)) or (c) distributed to any individual outside a Restricted Territory who is a resident thereof in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction. This Presentation is being made available on the basis that recipients keep confidential any information contained herein, whether orally or in writing, in connection with SVP. This Presentation is confidential and must not be copied, reproduced, published, distributed, disclosed or passed to any other person at any time without the prior written consent of SVP. Prospective investors should not construe the contents of this Presentation as legal, tax, investment or other advice. All prospective investors should make their own enquiries and consult their own advisers as to legal, tax, investment, and related matters concerning an investment in SVP. By accepting a copy of this Presentation you agree to be bound by the foregoing provisions.
2
3
Short term cash generative business SV Pharma has acquired ethanol extraction and refining equipment from a leading US manufacturer to install in German facility. Will produce high grade CBD distillate/isolate for wholesale. Generating fast cash flow. Extraction scheduled to commence in Q1 2020.
4
4
Providing a foothold in the largest medical cannabis market in Europe SV Pharma holds a trading licence for THC in Germany which includes import / export and distribution. Licence currently allows for trading of 160kg of flower per year. Work underway to expand licence, increasing capacity, for full commercialisation.
Unlimited THC cultivation and processing licence via JV with leading pharma company JV with Zada Pharmaceuticals Bosnia, GMP certified THC cultivation, extraction and processing facility SV Pharma holds 62% of JV with Zada to contribute an initial €6 mill towards land and buildings. Construction scheduled to commence in Q2 2020.
5
6
(1) Brightfield Group - 26 March 2019
7
SV Pharma is expecting delivery of its first 500 Gallon Industrial Performance Integrated Extraction and Recovery Solution on site in Germany in Q1 2020.
scalability
innovative extraction technology in the marketplace
specific products
8
8
relationships with farmers
changing opportunities in the market
9
10
11
Burim Thaci – Chairman
Burim is an experienced executive whose prior accomplishments include leading and expanding
pharmaceutical production companies over the past ten years. Three and a half years of this was focused on investment and management in the medical cannabis
experience, he is well-versed in project financing, management and financial restructuring and change management
Greg Kuenzel – CEO
Greg holds a Bachelor of Business Degree and is a Fellow of the Institute of Chartered Accountants in England & Wales. He has many years of experience in providing accounting and corporate advice to public companies in a diverse range of industry sectors. For the past 15 years he has worked with predominantly UK listed companies holding senior financial and management positions. Greg is a partner of Heytesbury Corporate LLP. More recently he has advised a number
Europe. 12
Colby Riggle – Operations Director
Colby, as a native of California, has in excess of 15 years of experience in the cannabis space as both Master Grower for Calaveras Wellness Farms, Calaveras CA and The Cannabis Cooperative; and Head
has experience managing teams of growers (for both indoor and outdoor operations) and has overseen processing and extraction on an industrial scale including for the pharmaceutical sector
Nicola Baldwin – Corporate Counsel
Nicola has, for the last 10 years, worked with London- based City & Westminster Corporate Finance LLP as its in-house legal adviser. Prior to that she was employed by a city law firm, now DMH Stallard. Her experience includes corporate finance transactions, M&A and multi-jurisdictional IPOs. As well as being a practising solicitor, Nicola regularly sits as a Magistrate in Central London
Adrian Beeston – Executive Director
Adrian is a private investor who specialises in the financing and structuring of small to medium size businesses and the flotation of these companies on the US, English and Canadian Exchanges. Prior to this he was a Director of Thorpe-Beeston Investments Ltd, from 2002 until 2017. He moved to the UK from Canada in 2000, where he worked with Altium Capital, a major pan-European corporate finance house, where he focused primarily on the raising of private equity
Dr Bhardwaj has been working in phytomedicine for well over a decade, with a focus on cannabis and its medicinal properties for the past 10 years. Dr Bhardwaj and his team are currently undertaking R&D studies on numerous conditions, including nausea, loss
itching, glaucoma, epilepsy, asthma, psychiatric symptoms, hyperactivity disorder / ADHD, Alzheimer's disease, autoimmune and inflammatory diseases and
stage of several products created with the SV Pharma team scientists in Germany and Bosnia 13
Herman Groenewoudt – Commercial Director
Prior to joining SV Pharma, Herman was the CEO of C3 International B.V. Holding, which holds the Vitaponix branded patent in agriculture and organic nutrition. Herman has previous experience in the cannabis industry with a focus on nutrition. This includes agriculture and glass house operation experience on a 4-hectare facility in the Netherlands. Herman was also a director for international sales at ATCO Europe B.V. for more than 6 years. Herman achieved the rank of Lieutenant during his service in the Royal Netherlands Navy
Development Director
Dr Bolta has extensive experience in business development, product portfolio management, project management, intellectual property protection and
Certification training for the use of cannabis in patients, cultivation and processing. Dr Bolta is a chemical process engineer and a doctor
biotechnology (plant biotechnology).
14
Funding Vehicle SV Pharma Limited Total Investment Amount £3,000,000 Pre-Money Valuation £20,000,000 Timing December 2019/January 2020
15